Evidence map›Paper›PMID 34758195›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022

Engagement of vascular early response genes typifies mild cognitive impairment.

Pavel Katsel, Peter Fam, Weilun Tan, Sonia Khan, Miguel Gama-Sosa, Rita De Gasperi, Panos Roussos, Ari Robinson, Itzik Cooper, Michal Schnaider-Beeri and 1 more

Open access · greenAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Pavel KatselDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-8076-0162
Peter FamDepartment of Neuroscience, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Weilun TanDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sonia KhanDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Miguel Gama-SosaDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Rita De GasperiDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Panos RoussosDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ari RobinsonThe Joseph Sagol Neuroscience Center Tel-Hashomer, Ramat-Gan, Israel.
Itzik CooperThe Joseph Sagol Neuroscience Center Tel-Hashomer, Ramat-Gan, Israel.
Michal Schnaider-BeeriDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Vahram HaroutunianDepartment of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Icahn School of Medicine at Mount Sinai · USSheba Medical Center · ILAllen Institute for Brain Science · USJames J. Peters VA Medical Center · US

Funding

Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HILLEL GROSSMAN · 2020 to 2026
$31.0M
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's DiseaseU01AG046170 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, MINGHUI, ZHANG, BIN · 2013 to 2022
$26.0M
Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer DiseaseR01AG067025 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FINKBEINER, STEVEN M, HAROUTUNIAN, VAHRAM · 2019 to 2023
$11.8M
TO ADMINISTRATIVELY DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2020 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2025, CLOSING OF THE PERIOD OF AVAILABI75N95019C00049 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM · 2019 to 2025
$11.8M
Traumatic Brain Injury and Repetitive Head Impacts: Contributions to AD/ADRD and CTE Neuropathology and Resulting Clinical SyndromesU54NS115266 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MCKEE, ANN C. · 2019 to 2023
$10.3M
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer DiseaseR01AG065582 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, ROUSSOS, PANAGIOTIS · 2020 to 2024
$9.9M
Integrative Network Modeling of Cognitive Resilience to Alzheimer's DiseaseR01AG057907 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, HAROUTUNIAN, VAHRAM · 2017 to 2021
$6.3M
Dynamic RNA Modifications in human brain development and autismU01MH116441 · NIMH · EMORY UNIVERSITY · PI JIN, PENG · 2018 to 2022
$4.9M
Systems modeling of shared and distinct molecular mechanisms underlying comorbid Major Depressive Disorder and Alzheimer's diseaseR01AG062355 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, SALTON, STEPHEN R · 2018 to 2022
$4.7M
Molecular Characterization and Validation of Gender Differences in Alzheimers Disease PathogenesisRF1AG054014 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, ZHANG, BIN · 2016 to 2016
$4.2M
Peripheral and brain levels of advanced glycation end products AGEs and incident Alzheimers disease and neuropathologyR01AG053446 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHNAIDER BEERI, MICHAL, URIBARRI, JAIME · 2016 to 2021
$3.8M
Inflammation, long-term diabetes characteristics, and cognitive declineR01AG034087 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHNAIDER BEERI, MICHAL · 2009 to 2014
$3.7M
NIA NIH HHS P30 AG066514NIA NIH HHS R01 AG034087NIA NIH HHS R01 AG051545NIA NIH HHS R01 AG053446NIA NIH HHS R01 AG057907NIA NIH HHS R01 AG062355NIA NIH HHS R01 AG065582NIA NIH HHS R01 AG067025NIA NIH HHS R21 AG043878NIA NIH HHS RF1 AG054014NIA NIH HHS RF1 AG057440NIA NIH HHS U01 AG046170NIDA NIH HHS 75N95019C00049NIDA NIH HHS U01 DA048279NIH HHS S10 OD026880NIH HHS S10 OD030463NIMH NIH HHS U01 MH116441NINDS NIH HHS U54 NS115266RRD VA I21 RX002876RRD VA I21 RX003459
6 · The paper itself

Abstract

introductionMolecular responses in the brains of persons with mild cognitive impairment (MCI), the earliest transitional state between normal aging and early Alzheimer's disease (AD), are poorly understood.

methodsWe examined AD-related neuropathology and transcriptome changes in the neocortex of individuals with MCI relative to controls and temporal responses to the mild hypoxia in mouse brains.

resultsSubsets of vascular early response to hypoxia genes were upregulated in MCI prior to the buildup of AD neuropathology. Early activation of pro-angiogenic hypoxia-inducible factor signaling in response to mild hypoxia was detected in mouse brains similar to those that were altered in MCI. Protracted responses to hypoxia were characterized by activation of phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt)-the mammalian target of rapamycin (mTOR) pathways in brain microvessel isolates. DISCUSSION: These findings suggest that cerebrovascular remodeling is an important antecedent to the development of dementia and a component of the homeostatic response to reduced oxygen tension in aging prior to the onset of AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionNeocortexAmyloid beta-PeptidesAnimalsBiomarkersHypoxiaMicePhosphatidylinositol 3-Kinasestau ProteinsAmyloid beta-PeptidesBiomarkersPhosphatidylinositol 3-Kinasestau ProteinsAlzheimer's diseaseamyloid betaendothelial cellsgene expressionhypoxiamild cognitive impairmentneurodegenerationneurovascular unitTau proteinvascular remodeling

Identifiers

PMID34758195
PMCPMC10878080
OpenAlexW3212527621

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.